Pharmacological revascularisation in coronary and peripheral vascular disease

Bibliography

• CHARNEY R, COHEM M: The role of the coronary collateral circulation in limiting myocardial ischemia and infarct size. Am. Heart J. (1993)126:937–945.
   PubMed Web of Science ®Google Scholar
• COUFFINHAL T, SILVER M, KEARNEY M et al: Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE4- mice. Circulation (1999) 99(24):3188–3198.
   PubMed Web of Science ®Google Scholar
• RIVARD A, SILVER M, CHEN D, KEARNEY M et al.: Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am. J. Pathol (1999) 154(2):355–363.
   PubMed Web of Science ®Google Scholar
• RIVARD A, FABRE JE, SILVER M et al.: Age-dependent impairment of angiogenesis. Circulation (1999) 99(1):111–120.
   PubMed Web of Science ®Google Scholar
• YILMAZ MB, BIYIKOGLU SF, AKIN Y et al.: Obesity is associated with impaired coronary collateral vessel development. Int. Obes. Relat. Metab. Disord. (2003) 27(12):1541–1545.
   PubMed Web of Science ®Google Scholar
• LEE LY, PATEL SR, HACKETT NR et al: Focal angiogenesis therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann. Thorac. Surg. (2000) 69(1):14–23.
   PubMed Web of Science ®Google Scholar
• SCHWARZ ER, SPEAKMAN MT, PATTERSON M et al.: Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat-angiogenesis and angioma formation. J. Am. Coll. Cardio. (2000) 35(5):1323–1330.
   PubMed Web of Science ®Google Scholar
• TANAKA E, HATTAN N, ANDO K et al: Amelioration of microvascular myocardial ischemia by gene transfer of vascular endothelial growth factor in rabbits. J. Thome. Cardiovasc. Surg. (2000) 120(4):720–728.
   PubMed Web of Science ®Google Scholar
• SATO K, WU T, LAHAM RJ et al.: Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. J. Am. Coll. Cardiol (2001) 37(2):616–623.
   PubMed Web of Science ®Google Scholar
• •An animal model study evaluating the efficacy of intracoronary or intravenous administration of recombinant VEGF-165 treatment for myocardial ischaemia.
   Google Scholar
• MACK CA, PATELI SR, SCHWARZ EA et al.: Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. Thorac. Cardiovasc. Surg. (1998) 15(1):168–76; discussion 176–177.
   Google Scholar
• HENDEL RC, HENRY TD, ROCHA-SINGH K et al: Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation (2000) 101(2):118–121.
   PubMed Web of Science ®Google Scholar
• ASAHARA T, TAKAHSHI T, MASUDA H et al.: VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. (1999) 18(14):3964–3972.
   PubMed Web of Science ®Google Scholar
• ••Study demonstrating the mobilisation of BMCs by VEGE
   Google Scholar
• KALKA C, TEHRANI H, LAUDENBERG B et al.: VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. Ann. Thome. Surg. (2000) 70(3):829–834.
   PubMed Web of Science ®Google Scholar
• CARMELIET P, FERREIRA V, BREIER G et al.: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. (1996) 380(6573)435–439.
   Google Scholar
• FREEDMAN SB, ISNER JM: Therapeutic angiogenesis for coronary artery disease. Ann. Intern. Med. (2002) 136(1):54–71.
   PubMed Web of Science ®Google Scholar
• MANNINEN HI, MAKINEN K: Gene therapy techniques for peripheral arterial disease. Cardiovasc. Inter vent. Radial. (2002) 25(2):98–108.
   PubMed Web of Science ®Google Scholar
• BAUTERS C, ASAHARA T, ZHENG LP et al.: Recovery of disturbed endothelium-dependent flow in the collateral-perfused rabbit ischemic hindlimb after administration of vascular endothelial growth factor. Circulation (1995) 91(11):2802–2809.
   PubMed Web of Science ®Google Scholar
• LAZAROUS DF, SHOU M, SCHEINOWITZ M et al.: Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation (1996) 94(5):1074–1082.
   PubMed Web of Science ®Google Scholar
• HARIAWALA MD, HOROWITZ JR, ESAKOF D et al.: VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. Surg. Res. (1996) 63(1):77–82.
   PubMed Web of Science ®Google Scholar
• HENRY TD, ROCHA-SINGH K, ISNER JM et al.: Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am. Heart J. (2001) 142(5):872–880.
   PubMed Web of Science ®Google Scholar
• HENRY TD, ANNEX BH, McKENDALL GR et al: The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation (2003) 107(10):1359–1365.
   PubMed Web of Science ®Google Scholar
• ••Important clinical study on the effect ofVEGF-165 protein therapy in ischaemia and vascular angiogenesis.
   Google Scholar
• LOPEZ JJ, LAHAM RJ, CARROZZA JP et al.: Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response. Am. Physiol (1997) 273(3 Pt 2):H1317–H1323.
   Google Scholar
• BANAI S, JAKLITSCH MT, SHOU M: Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation (1994) 89(5):2183–2189.
   PubMed Web of Science ®Google Scholar
• MAH C, BYRNE BJ, FLOTTE TR: Virus-based gene delivery systems. Clin. Pharmacokinet. (2002) 41(12):901–911.
   PubMed Web of Science ®Google Scholar
• GILGENKRANTZ H, DUBOC D, JUILLARD V et al: Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: role of the immune response. Hum. Gene Ther. (1995) 6(10):1265–1274.
   PubMed Web of Science ®Google Scholar
• CHAN SY, LI K, PICCOTTI JR et al.: Tissue-specific consequences of the anti-adenoviral immune response: implications for cardiac transplants. Nat. Med. (1999) 5(10):1143–1149.
   PubMed Web of Science ®Google Scholar
• GOWDAK LH, POLIAKOVA L, LI Z et al.: Induction of angiogenesis by cationic lipid-mediated VEGF165 gene transfer in the rabbit ischemic hindlimb model." Vasc. Surg. (2000) 32(2):343–352.
   Google Scholar
• HEDMAN M, HARTIKAINEN J, SYVANNE M et al.: Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: Phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation (2003) 107(21):2677–2683.
   PubMed Web of Science ®Google Scholar
• ••Clinical study that shows safety ofVEGF-165 adenovirus therapy.
   Google Scholar
• MOHLER ER 3rd, RAJAGOPALAN S, OLIN JW et al: Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a Phase I trial. Vasc Med. (2003) 8(1):9–13.
   PubMed Web of Science ®Google Scholar
• ••Report of Phase I trial that shows thebeneficial effects of VEGF-121 gene therapy in critical limb ischemia.
   Google Scholar
• RASMUSSEN HS, RASMUSSEN CS, MACKO J: VEGF gene therapy for coronary artery disease and peripheral vascular disease. Cardiovasc. Radial-. Med. (2002) 3(2):114–117.
   PubMedGoogle Scholar
• ••Demonstrates the importance of VEGFgene therapy in promoting vascular angiogenesis for coronary artery disease and peripheral vascular disease.
   Google Scholar
• RAJAGOPALAN S, MOHLER ER et al: Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease. Circulation (2003) 108:1933–1938.
   PubMed Web of Science ®Google Scholar
• RIBATTI D, VACCA A, PRESTA M: The discovery of antigenic factors: A historical review. Gen. pharinacol (2002) 35(5):227–231.
   Google Scholar
• •Good review on antigenic factors.
   Google Scholar
• OHARA N, KOYAMA H, MIYATA T et al.: Adenovirus-mediated ex vivo gene transfer of basic fibroblast growth factor promotes collateral development in a rabbit model of hind limb ischemia. Gene Ther: (2001) 8(11):837–845.
   PubMed Web of Science ®Google Scholar
• HUGHES GC, BISWAS SS, YIN B et al: Therapeutic angiogenesis in chronically alchemic porcine myocardium: comparative effects of buff and VEGE Ann. Thorax Surg. (2004) 77(3):812–818.
   PubMed Web of Science ®Google Scholar
• LEDERMAN RJ, MENDELSOHN FO, ANDERSON RD et al: Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudicating (the TRAFFIC study): a randomized trial. Lancet (2002) 359(9323):2053–2058.
   PubMed Web of Science ®Google Scholar
• ••A randomised clinical trial that showssome improvement can be obtained with FGF-2 protein therapy for intermittent daudicating.
   Google Scholar
• COMERICA AL, THRUM RC et al: Naked plastid DNA encoding fibroblast growth factor Type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a Phase I trial.Vass. Surge. (2002) 35:930–936.
   PubMed Web of Science ®Google Scholar
• LAHAM RJ, SELLKE FW, EDELMAN ER et al.: Local per vascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a Phase I randomized, double-blind, placebo-controlled trial. Circulation (1999) 100(18):1865–1871.
   PubMed Web of Science ®Google Scholar
• GRINES C, RUBANYI GM,
   Google Scholar
• KLEIMAN NS et al.: Antigenic gene therapy trial (AGENT) in patients with stable angina pectoris. Circulation (2002) 105:1291–1297.
   PubMed Web of Science ®Google Scholar
• GRINES CL, WATKINS MW, MAHMARIAN JJ et al.: Angiogene GENe Therapy (AGENT-2) Study Group. A randomized, double blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. I Am. Coll Cardiol (2003) 42(8):1339–1347.
   Google Scholar
• ••Clinical study that shows significant improvement with adenoviral vectors expressing FGF-4 gene therapy on myocardial perfusion.
   Google Scholar
• GIACCIA A, SIIM BG, JOHNSON RS: HIF- la as a target for drug development. Nat. Rev Drug Discov. (2003) 2(10):803–811.
   PubMed Web of Science ®Google Scholar
• ••Good review on HIF-la biology and rolein disease.
   Google Scholar
• JIANG C, LU H, VINCENT KA et al.: Gene expression profiles in human cardiac cells subjected to hypoxia or expressing a hybrid form of HIF-la. Physiol Genomics (2002) 8(1):23–32.
   PubMed Web of Science ®Google Scholar
• VINCENT KA, SHYU KG, LUO Yet al.: Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF- 1 aNP16 hybrid transcription factor. Circulation (2000) 102(18):2255–2261.
   Google Scholar
• RAJAGOPALAN S, OLIN Jet al.: Harnessing the response to hypoxia: use of a constitutively active hypoxia- inducible factor-1a transgene in no-option critical limb ischemia. Circulation (2003) 108(17):IV–442.
   Google Scholar
• HIRAI H: Stem cells and regenerative medicine. Hum. Cell. (2002) 15(4):190–198.
   PubMedGoogle Scholar
• KAMIHATA H, MATSUBARA H, NISHIUE T et al.: Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation (2001) 104(9):1046–1052.
   PubMed Web of Science ®Google Scholar
• SCHATTEMAN GC, HANLON HD, RAO C et al.: Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. Clin. Invest. (2000) 106(4):571–578.
   Google Scholar
• MENASCHE P, HAGEGE AA, SCORSIN M et al.: Myoblast transplantation for heart failure. Lancet (2001) 357(9252):279–280.
   PubMed Web of Science ®Google Scholar
• STRAUER BE, BREHM M, ZEUS T et al.: Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation (2002) 106(15):1913–1918.
   PubMed Web of Science ®Google Scholar
• ASSMUS B, SCHACHINGER V, TEUPE C et al.: Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction. Circulation (2002) 106(24):3009–3017.
   PubMed Web of Science ®Google Scholar
• STAMM C, WESTPHAL B, KLEINE HD et al.: Autologous bone marrow stem cell transplantation for myocardial regeneration. Lancet (2003) 361(9351):45–46.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI T, KALKA C, MASUDA H et al.: Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. (1999) 5(4):434–438.
   PubMed Web of Science ®Google Scholar
• ASAHARA T, TAKESHITA S, TSURUMI Y et al.: Arterial gene therapy: a molecular biological perspective for the treatment of arterial ischemia. Z Kardiol (1997) 86(1):65–69.
   PubMedGoogle Scholar
• SEILER C, POHL T, WUSTMANN K et al.: Promotion of collateral growth by gametocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation (2001) 104(17):2012–2017.
   PubMed Web of Science ®Google Scholar
• ••Clinical study showing the importance ofpromoting collateral growth as therapeutic approach in patients with CAD.
   Google Scholar
• LAPIDOT T: Mechanism of human stem cell migration and repopulation of NOD/ SCID and B2mnull NOD/SCID mice. The role of SDF-1/CXCR4 interactions. Ann. NY Acad. ScL (2001) 938:83–95.
   PubMed Web of Science ®Google Scholar
• CARMELIET P, MOONS L, LUTTUN A et al.: Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. (2001) 7(5):575–583.
   PubMed Web of Science ®Google Scholar
• AOKI M, MORISHITA R, TANIYAMA Y, KANEDA Y et al.: Therapeutic angiogenesis induced by hepatocyte growth factor: potential gene therapy for ischemic diseases. Atheroscler: Thromb. (2000) 7(2):71–76.
   Google Scholar
• ZHONG J, ELICEIRI B, STUPACK D et al.: Neovascularization of ischemic tissues by gene delivery of the extracellular matrix protein Del-1. .1 Clin. Invest.(2003) 112(1):30–41.
   Google Scholar
• RAJAGOPALAN S, OLINS JVV et al.: Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a Phase II multicenter, double-blind, placebo-controlled trial of VOLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease. Human gene therapy (2004) 15:619–624.
   PubMed Web of Science ®Google Scholar